Lung cancer study asks: what matters most to patients and their doctors?

NCT ID NCT06448793

Completed Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This study interviews 55 patients with resectable non-small cell lung cancer and their doctors in the US, Germany, and Japan. The goal is to understand what treatment features they value most, such as effectiveness or side effects. Results may help align care with patient priorities.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors and patients make better-informed treatment decisions for early-stage lung cancer.
What could go wrong: This is an observational study with only 55 participants, so findings may not apply to everyone. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Evidera

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.